Sign In
Buy TBPH
$16.86
+0.0100 (+0.0593%)
At Close: Jul 31, 2026
Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet
03:00pm, Friday, 18'th Feb 2022 Zacks Investment Research
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet
11:39am, Friday, 18'th Feb 2022
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
04:50pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y
04:48pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
05:03pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.
Tracking Seth Klarman's Baupost Group Holdings - Q4 2021 Update
08:36am, Tuesday, 15'th Feb 2022 Seeking Alpha
Seth Klarman’s 13F portfolio value decreased from $10.88B to $10.13B this quarter. Baupost Group added Fiserv while dropping eBay and International Flavors & Fragrances.
Zacks.com featured highlights include Theravance Biopharma, PattersonUTI Energy and Select Energy Services
03:43pm, Friday, 11'th Feb 2022 Zacks Investment Research
Theravance Biopharma, PattersonUTI Energy and Select Energy Services are included in this blog.
Orphazyme, Y-mAbs Therapeutics top healthcare gainers; ProQR, Senseonics lead losers pack
03:01pm, Friday, 11'th Feb 2022 Seeking Alpha
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%
GlaxoSmithKline speculated to be targeting possible acquisition of Theravance Bio
01:15pm, Friday, 11'th Feb 2022 Seeking Alpha
GlaxoSmithKline (GSK) is speculated to be potentially targeting an acquisition of Theravance Biopharma (TBPH). The "rumour mill" is talking about a potential GSK bid for Theravance
3 Best Stocks to Buy Right Away for Earnings Acceleration
02:34pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.
3 Best Stocks to Buy Right Away for Earnings Acceleration
10:46am, Thursday, 10'th Feb 2022
Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 | MarketScreener
11:01am, Wednesday, 09'th Feb 2022 MarketScreener
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday,… | February 9, 2022
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
06:00am, Wednesday, 09'th Feb 2022
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2021 financial results and provide a business update after market close on W
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
02:09pm, Tuesday, 08'th Feb 2022 Zacks Investment Research
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.
Lannett (LCI) Reports Q2 Loss, Misses Revenue Estimates
11:25pm, Thursday, 03'rd Feb 2022 Zacks Investment Research
Lannett (LCI) delivered earnings and revenue surprises of -21.88% and 14.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
